Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Capital Employed (2016 - 2025)

Enanta Pharmaceuticals filings provide 13 years of Return on Capital Employed readings, the most recent being 28.06% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 713.0% to 28.06% in Q4 2025 year-over-year; TTM through Dec 2025 was 28.06%, a 713.0% increase, with the full-year FY2025 number at 30.47%, up 316.0% from a year prior.
  • Return on Capital Employed hit 28.06% in Q4 2025 for Enanta Pharmaceuticals, up from 35.22% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 18.9% in Q1 2021 to a low of 42.34% in Q1 2023.
  • Median Return on Capital Employed over the past 5 years was 35.22% (2025), compared with a mean of 33.52%.
  • Biggest five-year swings in Return on Capital Employed: crashed -2117bps in 2021 and later skyrocketed 713bps in 2025.
  • Enanta Pharmaceuticals' Return on Capital Employed stood at 31.78% in 2021, then decreased by -15bps to 36.47% in 2022, then dropped by -2bps to 37.1% in 2023, then rose by 5bps to 35.19% in 2024, then grew by 20bps to 28.06% in 2025.
  • The last three reported values for Return on Capital Employed were 28.06% (Q4 2025), 35.22% (Q3 2025), and 36.2% (Q2 2025) per Business Quant data.